HIGHLIGHTS
SUMMARY
High-risk and progressive or relapsed cancers in children remain a significant challenge in pediatric oncology, with progression-free and overall survival rates of 10% and 20% at two years, respectively, despite intense multimodal treatment approaches1. The authors did not observe substantial npj Precision Oncology 94 differences in the average shipment time and yield of tumor cells for drug screens in Germany versus cases from other countries. Overall, the fraction of tumor cells remained largely stable or was further enriched during preculture, with ~50-90% tumor cells after dissociation and ~77-87% tumor cell . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.